These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 37855081)
1. Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China. Kang S; Wang X; Pan Z; Liu H Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):285-292. PubMed ID: 37855081 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of toripalimab plus chemotherapy for advanced esophageal squamous cell carcinoma. Xu K; Wu H; Zhou C; Bao Y; Yu M; Zhang L; Li X Int J Clin Pharm; 2023 Jun; 45(3):641-649. PubMed ID: 36800145 [TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and Cisplatin as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma. Fang R; Wang S; Liu Y; Xu J Adv Ther; 2023 Mar; 40(3):1019-1030. PubMed ID: 36622553 [TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China. Zheng Z; Fang L; Cai H; Zhu H Expert Rev Pharmacoecon Outcomes Res; 2023; 23(6):683-690. PubMed ID: 37086175 [TBL] [Abstract][Full Text] [Related]
5. Cost‑effectiveness analysis of tislelizumab plus chemotherapy in Chinese patients with advanced or metastatic oesophageal squamous cell carcinoma. Zhang L; Su H; Liang X; Chen X; Li Y Sci Rep; 2024 Jul; 14(1):17734. PubMed ID: 39085374 [TBL] [Abstract][Full Text] [Related]
6. Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis. Kang S; Yin J Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; 24(5):653-659. PubMed ID: 38506058 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China. Liu S; Jiang N; Dou L; Li S Front Immunol; 2023; 14():1172242. PubMed ID: 37215110 [TBL] [Abstract][Full Text] [Related]
8. First-Line Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma:A Cost-Effectiveness Analysis. Zheng Z; Chen H; Cai H; Zhu H Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):397-404. PubMed ID: 38031985 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China. Zhang M; Xu K; Lin Y; Zhou C; Bao Y; Zhang L; Li X Front Immunol; 2023; 14():1169752. PubMed ID: 37313403 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma. Liu L; Wang L; Chen L; Ding Y; Zhang Q; Shu Y Front Immunol; 2023; 14():1092385. PubMed ID: 36756110 [TBL] [Abstract][Full Text] [Related]
11. Toripalimab plus chemotherapy in American patients with recurrent or metastatic nasopharyngeal carcinoma: A cost-effectiveness analysis. Lian D; Gan Y; Xiao D; Xuan D; Chen Y; Yang Y Cancer Med; 2024 May; 13(10):e7243. PubMed ID: 38752448 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China. He C; Mi X; Xu G; Xu X; Xin W; Zhong L; Zhu J; Shu Q; Fang L; Ding H PLoS One; 2024; 19(5):e0302961. PubMed ID: 38748691 [TBL] [Abstract][Full Text] [Related]
13. First-line serplulimab plus chemotherapy versus chemotherapy in PD-L1-positive esophageal squamous-cell carcinoma: a cost-effectiveness analysis. Liang X; Meng M; Qin S; Chen X; Li Y Sci Rep; 2024 Jun; 14(1):14496. PubMed ID: 38914660 [TBL] [Abstract][Full Text] [Related]
14. Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis. Lu S; Lou Y; Rong Y; Huang Z; Lin X; Chen J; Luo K Clin Drug Investig; 2023 Aug; 43(8):643-652. PubMed ID: 37542611 [TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More. Zheng Z; Lin J; Zhu H; Cai H Front Public Health; 2022; 10():893387. PubMed ID: 35774581 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma. Chen P; Fu C; Shen L; Fei Z; Luo M; Chen Y; Li H BMC Health Serv Res; 2024 May; 24(1):676. PubMed ID: 38807104 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma. Gong J; Shang J; Su D; Qian X; Liu G; Sun Z Expert Rev Pharmacoecon Outcomes Res; 2023; 23(6):709-717. PubMed ID: 37190977 [TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of toripalimab combined with chemotherapy in the treatment of non-small cell lung cancer. Wang H; Long Y; Xu Y; Liao L; Zhou Y Front Public Health; 2023; 11():1137255. PubMed ID: 37033059 [TBL] [Abstract][Full Text] [Related]
19. A cost-effectiveness analysis of first-line toripalimab plus chemotherapy in advanced nonsquamous non-small cell lung cancer in China. Zheng Z; Zhu G; Cao X; Cai H; Zhu H Expert Rev Clin Pharmacol; 2023 Mar; 16(3):267-273. PubMed ID: 36877089 [TBL] [Abstract][Full Text] [Related]
20. Toripalimab plus chemotherapy in the treatment of metastatic triple-negative breast cancer: a cost-effectiveness analysis. Cai H; Huang L; Zheng Z Front Public Health; 2024; 12():1421826. PubMed ID: 39135924 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]